DISEASE INDICATIONS: Risk of cardiovascular events, Hypercholesterolemia
MANUFACTURER: Amgen Inc.
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Repatha (evolocumab) is a medication that reduces the risk of cardiovascular disease through decreasing low-density lipoprotein (LDL) cholesterol levels by targeting and inhibiting PCSK9. It is administered subcutaneously once every two weeks or once a month and should be stored in a refrigerator. Repatha is used as an adjunct to diet and other lipid-lowering therapies.